Young & Partners Chemical Financing: Reflections on 2023 and Outlook (March 2024)
Proprietary data and analysis of chemical financing trends in 2023 and the current outlook.
Biopharma Industry Business Review and Outlook (Pharmaceutical Executive, March 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in 2023, and the outlook for 2024.
Young & Partners 2023 Chemical Conference: Speakers Roundtable- What Does the Future Hold?
Peter Young, Young & Partners Mathias Zachert, CEO of Lanxess Kamal Navarthy, President of Reliance Dewey Johnson, SVP Chemical Market Analytics
Young & Partners Chemical Financing: Reflections on 2023 and Outlook (March 2024)
Proprietary data and analysis of chemical financing trends in 2023 and the current outlook.
Biopharma Industry Business Review and Outlook (Pharmaceutical Executive, March 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in 2023, and the outlook for 2024.
Young & Partners 2023 Chemical Conference: Speakers Roundtable- What Does the Future Hold?
Peter Young, Young & Partners Mathias Zachert, CEO of Lanxess Kamal Navarthy, President of Reliance Dewey Johnson, SVP Chemical Market Analytics
Young & Partners Chemical Financing: Reflections on 2023 and Outlook (March 2024)
Proprietary data and analysis of chemical financing trends in 2023 and the current outlook.
Biopharma Industry Business Review and Outlook (Pharmaceutical Executive, March 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in 2023, and the outlook for 2024.
Young & Partners 2023 Chemical Conference: Speakers Roundtable- What Does the Future Hold?
Peter Young, Young & Partners Mathias Zachert, CEO of Lanxess Kamal Navarthy, President of Reliance Dewey Johnson, SVP Chemical Market Analytics
Young & Partners Chemical Financing: Reflections on 2023 and Outlook (March 2024)
Proprietary data and analysis of chemical financing trends in 2023 and the current outlook.
Biopharma Industry Business Review and Outlook (Pharmaceutical Executive, March 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in 2023, and the outlook for 2024.
Young & Partners 2023 Chemical Conference: Speakers Roundtable- What Does the Future Hold?
Peter Young, Young & Partners Mathias Zachert, CEO of Lanxess Kamal Navarthy, President of Reliance Dewey Johnson, SVP Chemical Market Analytics